NCT07624994Not yet recruitingPhase 2
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 29 May 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Jul 2028
- Lead sponsor
- Centre Jean Perrin
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07624994
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 1 Oct 2026 to the primary completion date, 1 Jul 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ongoing use of non-steroidal anti-inflammatory drugs,
Other illness
- History of osteoarticular hand surgery.
- History of hand soft tissue surgery in the past 6 months
- History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,
- Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study.
- RA Group:
- Patients with a history of hand DOA
Age
- Patients or patients 18 years old,
Other
- Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,
- Pregnant or breastfeeding patient,
- IMC\>30,
- Persons deprived of their liberty, under guardianship/curatorship, or safeguarding of justice,
- Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment.
Who the study is looking for
- Karnofsky index \> 70%
- Obtaining written, signed and dated informed consent
- Affiliation to a health insurance plan
- For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period.
- Ability and willingness to respect study visits, exams as well as protocol.
- RA Group:
- certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR/EULAR criteria,
- symptomatic (finger pain \> 4 /10 on a numerical scale),
- active synovitis (clinical and ultrasound),
- Group DOA:
- certain diagnosis of symptomatic DOA less than 5 years old (finger pain \> 4 /10 on a numerical scale),
- stopping NSAIDs for at least 8 days before the injection,
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Unknown status |
| Centre Jean Perrin Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.